Compare AU

Compare VETH vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard Ethically Conscious Australian Shares ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Ethically Conscious Australian Shares ETF (VETH) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VETH

CURE

Popularity

Low

Low

Pearlers invested

799

83

Median incremental investment

$993.50

$619.50

Median investment frequency

Monthly

Monthly

Median total investment

$2,369.50

$1,437.24

Average age group

26 - 35

> 35


Key Summary

VETH

CURE

Strategy

VETH.AX was created on 2020-10-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious Australian Shares ETF seeks to track the return ofthe FTSE Australia 300 Choice Index before taking into account fees, expenses and tax.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Commonwealth Bank of Australia (10.17 %)

CSL Ltd. (9.69 %)

National Australia Bank Ltd. (5.54 %)

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Top 3 industries

Financials (34.37 %)

Materials (18.25 %)

Health Care (13.54 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

Australia (98.46 %)

New Zealand (1.54 %)

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.17 %

0.45 %


Key Summary

VETH

CURE

Issuer

Vanguard

Global X

Tracking index

FTSE Australia 300 Choice Index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.17 %

0.45 %

Price

$67.72

$51.33

Size

N/A

$36.301 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

3.73 %

4.24 %

Market

ASX

ASX

First listed date

13/10/2020

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

VETH

CURE

Popularity

Low

Low

Pearlers invested

799

83

Median incremental investment

$993.50

$619.50

Median investment frequency

Monthly

Monthly

Median total investment

$2,369.50

$1,437.24

Average age group

26 - 35

> 35


Pros and Cons

VETH

CURE

Pros

  • Higher exposure to AU market

  • Lower management fee

  • Higher price growth

  • Higher exposure to US market

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower distribution yield

  • Lower exposure to AU market

  • Higher management fee

  • Lower price growth

VETH

CURE

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield

Home